Viridian Therapeutics, Inc.
VRDNBiotechnology
$24.80+2.18%As of Oct 29vs prior close
- Market cap
- $2.8B
- From 52W high
- −26.58%
- EPS (YE23)
- -$5.31
- Revenue (LTM)
- $71.1M
- Net margin
- -544.06%
Nomior Score
34
Steady ProfileBottom 20% of the scored universe
Growth58
Quality35
Value45
Momentum37
Resilience31
Growth
+39.78%revenue a year over 9 fiscal years
YE16 $3.5MLTM $71.1M
Connections
Revenue to profitQ2 YE26
The operating loss was 44461% of revenue, narrower by 97895 pts on a year.
Who owns it
2funds